On September 29, 2026, Bristol Myers Squibb…disclosed safety concerns in its phase 3 clinical trials for admilparant, a drug candidate targeting idiopathic pulmonary ﬁbrosis, after identifying signiﬁcant risks of liver injury including a patient death linked to acute hepatic injury